Skip to main content

Table 3 Adverse events (G1-2 and G3-4) for ACTH vs TCH

From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

  ACTH Adverse events TCH Adverse events
G1-2 G3-4 G1-2 G3-4
Anemia 5 (20%) 4(16%) 4(25%) 7(44%)
Infection 3 (12%) 18(72%) 0 5(31.25%)
Neutropenia 5 (20%) 7(28%) 2(12.5%) 1(6%)
Hepatotoxicity 2 (8%) 10(40%) 1(6%) 4(25%)
Renal toxicity 2 (8%) 0 2(12.5%) 0
Cardiac toxicity
 Symptomatic dysfunction 8 (32%) 0 3(18.75%) 0
 Cardiac failure 0 0 0 0
\